Core Insights - Viking Therapeutics reported strong progress in its clinical pipeline, particularly with VK2735, which has shown promising results in obesity treatment [2][3][6] - The company announced a net loss of $90.8 million for Q3 2025, significantly higher than the $24.9 million loss in Q3 2024, primarily due to increased research and development expenses [11][14] - Viking's cash position remains robust at $715 million, providing sufficient resources for ongoing clinical trials and development programs [15] Clinical Pipeline Updates - VK2735, a dual agonist targeting GLP-1 and GIP receptors, achieved significant weight loss results in the Phase 2 VENTURE-Oral Dosing study, with reductions of up to 12.2% from baseline [2][6] - The Phase 3 VANQUISH trials for VK2735 are on schedule, with enrollment expected to complete by the end of 2025 for VANQUISH-1 and in Q1 2026 for VANQUISH-2 [3][5] - Viking is also advancing an oral formulation of VK2735, which has shown encouraging safety and efficacy in early studies, and plans to file an IND for its amylin agonist program in Q1 2026 [6][9][12] Financial Performance - Research and development expenses for Q3 2025 were $90 million, up from $22.8 million in Q3 2024, reflecting increased clinical study costs and regulatory services [8][12] - General and administrative expenses decreased to $8.6 million in Q3 2025 from $13.8 million in Q3 2024, mainly due to reduced legal and patent service costs [10] - For the nine months ended September 30, 2025, total operating expenses reached $228.6 million, compared to $104.7 million for the same period in 2024 [21] Upcoming Events and Presentations - Viking plans to present at several upcoming scientific conferences, including ObesityWeek and the American Heart Association Scientific Sessions, to discuss its clinical programs and findings [9][18] - The company will host a conference call to discuss its Q3 2025 financial results, providing further insights into its operations and future plans [16]

Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered ...